Algiax announces positive data from phase 2a proof of concept study evaluating AP-325 in patients with neuropathic pain
- Algiax Pharmaceuticals reported positive topline data from a Phase 2a trial of AP-325 for neuropathic pain.
- AP-325, a non-opioid small molecule, showed rapid and lasting pain reduction, with a high responder rate.
- The trial demonstrated significant improvements in sleep quality and reduced anxiety and depression scores.
- The study involved 99 participants across multiple European countries, showing a favorable safety profile.
Read more
